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Background: c-Met is widely known as a poor prognostic factor in various human malignancies. Previous studies
have suggested the involvement of c-Met and/or its ligand, hepatocyte growth factor (HGF), in esophageal squamous
cell carcinoma (ESCC), but the correlation between c-Met status and clinical outcome remains unclear. Furthermore,
the identification of a novel molecular therapeutic target might potentially help improve the clinical outcome of ESCC
patients.
Methods: The expression of c-Met and HGF was immunohistochemically assessed in 104 surgically obtained tissue
specimens. The correlation between c-Met/HGF expression and patients’ clinicopathological features, including survival,
was evaluated. We also investigated changes in cell functions and protein expression of c-Met and its downstream
signaling pathway components under treatments with HGF and/or c-Met inhibitor in ESCC cell lines.
Results: Elevated expression of c-Met was significantly correlated with tumor depth and pathological stage. Patients
with high c-Met expression had significantly worse survival. In addition, multivariate analysis identified the high
expression of c-Met as an independent prognostic factor. Treatment with c-Met inhibitor under HGF stimulation
significantly inhibited the invasive capacity of an ESCC cell line with elevated c-Met mRNA expression. Moreover,
c-Met and its downstream signaling inactivation was also detected after treatment with c-Met inhibitor.
Conclusions: The results of our study identified c-Met expression as an independent prognostic factor in ESCC
patients and demonstrated that c-Met could be a potential molecular therapeutic target for the treatment of ESCC
with elevated c-Met expression.
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Esophageal squamous cell carcinoma (ESCC) is an
aggressive malignancy. Recently, several molecular markers
have been identified as prognostic factors for ESCC, and
the development of preoperative chemo-irradiation, surgi-
cal techniques, and postoperative chemotherapy has been
reported [1]. However, the survival rate of ESCC patients* Correspondence: ozawa.youhei@opal.plala.or.jp
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creativecommons.org/publicdomain/zero/1.0/remains dismal [2]. In addition, molecular targeted therapy
has not been fully developed for ESCC. Therefore, the
discovery of novel therapeutic targets is considered pivotal
for the treatment of ESCC.
c-Met, a transmembrane receptor tyrosine kinase, is
composed of α- and β-chains connected by a disulfide
linkage [3]. It is activated upon the binding of hepato-
cyte growth factor (HGF) via auto-phosphorylation of its
tyrosine kinase domain, resulting in cell motility and
proliferation and possibly affecting clinical outcome [4].
Therefore, c-Met activation plays pivotal roles during
embryogenesis and wound repair [3]. However, such ac-
tivation also promotes tumor progression, invasion, andrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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of c-Met and/or its correlation with poor prognosis has
been reported in various human malignancies, including
lung cancer [5, 6], breast cancer [7, 8], head and neck
cancer [9–11], gastric cancer [12–14], colorectal cancer
[15], bladder cancer [16], uterine cervix carcinoma [17],
and esophageal adenocarcinoma [18]. In addition, the
frequency of c-Met gene amplification and mutation in
human malignancies have been reported to range from
1.4 % to 7.2 % for gene amplification [19–21] and 1.7 %Table 1 Relationship between c-Met/HGF expression and clinicopat
Variable c-Met expression
Low H
Age (mean = 64 years old) <64 15 3
≥64 17 3
Gender Male 27 5
Female 5 1
Smoking historya Presence 27 5
Absence 5 1
Alcohol consumption historya Presence 25 5
Absence 6 1
Tumor sizeb (mean = 48.7 mm) <48.7 20 3
≥48.7 12 3
Tumor differentiationb Well 9 1
Moderate 18 4
Poor 5 1
Growth patternb INFa 8 1
INFb 18 4
INFc 6 1
Lymphatic invasionb ly0 8 2
ly1–3 24 4
Vessel invasionb v0 11 1
v1–3 21 5
Tumor depthd T1/T2 17 2
T3/T4 15 5
Lymph node metastasisd N0 13 2
N1 19 4
Distant metastasisde M0 29 6
M1 3 6
Pathological staged I/II 23 3
III/IV 9 4
HGF expression Low 21 4
High 11 3
HGF hepatocyte growth factor, INF infiltration
aData were not available for a few patients
bHistopathological features based on the Japanese Classification of Esophageal Can
c indicates statistical significance
dTumor-node-metastasis (TNM) classification based on the 6th edition of the TNM c
eAll cases of distant metastasis were that of the supraclavicular lymph nodesto 3.3 % for mutation [19, 21] in lung cancer, 1.5 % to
10.2 % for amplification in gastric cancer [14, 22, 23],
2 % for amplification in esophagogastric adenocarcinoma
[24], 13.2 % for mutation in papillary renal carcinoma
[25], and 26.7 % for mutation in head and neck squamous
cell carcinoma [26]. Therefore, c-Met is currently consid-
ered a potential therapeutic target molecule in various
types of human malignancies [27]. Recently, the presence
of c-Met gene amplification has been reported in ESCC
[28]. However, the correlation between c-Met status andhological features
P-value HGF expression P-value
igh Low High
6 0.769 33 18 0.219
6 28 25
9 0.762 53 33 0.178
3 8 10
6 0.802 49 34 0.987
2 10 7
4 0.77 49 30 0.116
1 7 10
8 0.357 35 23 0.694
4 26 20
7 0.831 10 16 0.024c
5 39 24
0 12 3
8 0.901 16 10 0.568
3 37 24
1 8 9
3 0.475 22 9 0.097
9 39 34
5 0.141 16 10 0.73
7 45 33
0 0.013c 27 10 0.028c
2 34 33
3 0.39 27 9 0.014c
9 34 34
6 0.862 58 37 0.107
3 6




cer, 10th edition (Japan Esophageal Society 2009)
lassification of malignant tumors [31]
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the reported correlation of c-Met and/or HGF status with
various clinicopathological features of ESCC [29, 30].
Therefore, in this study, we examined the clinical and
biological significance of c-Met in ESCC and evaluated
the potential of c-Met as a molecular therapeutic target
using in vitro experiments.
Methods
Tissue samples
We examined tissue samples from 104 primary ESCC
patients who underwent surgery without neoadjuvant
therapy from January 2000 to December 2006 at the
Tohoku University Hospital, Sendai, Japan. The final
diagnosis was made based on the 6th edition of the
tumor-node-metastasis classification of malignant tu-
mors by the Union for International Cancer Control
[31]. Patients diagnosed with pT1a pathological stage
and/or variant tumor components were excluded from
the study. The post-surgery follow-up period was at least
5 years in all patients examined in this study. Clinico-
pathological variables of the patients examined are sum-
marized in Table 1. The study protocol was approved by
the Ethics Committee of the Tohoku University School
of Medicine (Accession No. 2012-1-213), and informed
consent was obtained from all patients prior to surgery.
Immunohistochemistry
Immunohistochemistry was performed using anti-c-Metβ
polyclonal antibody (IBL, Gunma, Japan; 1:50 dilution)
and anti-HGFα polyclonal antibody (IBL, Gunma, Japan;
1:100 dilution). All surgical pathology specimens, obtained
from the sites of deepest invasion, were sectioned at 3-μm
thickness. Antigen-retrieval was performed in 0.01 M
citrate buffer (pH 6.0) by heating in a microwave. The
slides were then washed with phosphate-buffered saline
(PBS) and incubated with protein blocking solution
(Histofine Kit; Nichirei, Tokyo, Japan) at room temperature.
They were reacted with the primary antibodies overnight
at 4 °C. Endogenous peroxidase activity was blocked by
incubating the reacted slides in 0.3 % hydrogen peroxidase
with methanol. Slides were then incubated with biotinylated
goat anti-rabbit IgG (Nichirei) and horseradish peroxidase-
conjugated streptavidin (Nichirei). The antigen-antibody
complex was visualized with 3.3′-diaminobenzidine and
counterstained with hematoxylin. Normal placenta was
used as the positive control for c-Met and HGF immunore-
activity. The absorption test was performed using each anti-
gen peptides (IBL, Gunma, Japan).
Evaluation of immunohistochemistry
All immunostained slides were evaluated by two authors
(YO and YN) without prior knowledge of any clinico-
pathological variables. Five different high-power fieldswere analyzed per slide, with each field containing more
than 100 carcinoma cells. The H-score was determined
using the percentage of immunopositive cells and their
immunointensity. Immunointensity was evaluated and
scored according to the following criteria: 0, completely
negative; 1+, weakly positive; 2+, moderately positive,
and 3+, markedly positive. The H-score was then cal-
culated by multiplying the percentage of immuno-
positive cells to the immunointensity score (H-score
ranging from 0 to 300). We also determined the opti-
mal cut-off values using the receiver operating charac-
teristic (ROC) curve method, which indicated that “40”
was the optimal cut-off for patients’ survival outcome
when analyzing c-Met and HGF immunohistochemistry
results (c-Met: 40.2, HGF: 40.8). It was also close to the
optimal cut-offs for tumor depth (c-Met: 42.8, HGF: 40.2)
and lymph node metastasis (c-Met: 55.0, HGF: 36.2). Cases
with an H-score below the cut-off value were tentatively
categorized as “low expression”, whereas those with an
H-score greater than the cut-off value were considered as
“high expression”.
Preoperative serum biochemical test and respiratory
function test
In order to evaluate the possible influence of inflammatory
processes upon c-Met and HGF expression, the preo-
perative levels of percent vital capacity (%VC), forced
expiratory volume in one second percentage (FEV 1.0 %),
C-reactive protein (CRP), the retention rate of indocyanine
green 15 min after administration (ICG-R15), aspartate
aminotransferase (AST), and alanine aminotransferase (ALT)
were evaluated because of the high frequency of alcohol
consumption and smoking history in ESCC patients.
Cell lines and culture
Three human ESCC cell lines (KYSE150, 170, and 180)
were purchased from the Health Science Research Re-
sources Bank (Tokyo, Japan). All cell lines were authenti-
cated by using STR analysis (BEX, Tokyo, Japan) in July
2014. The three cell lines were maintained according to
the manufacturer’s instruction. All cells were cultured at
37 °C in a 5 % CO2 incubator.
Pharmaceutical reagents
A small-molecule inhibitor for c-Met (PF-2341066) was
purchased from Selleck Chemicals (Houston, TX, USA).
PF-2341066 was reconstituted in dimethyl sulfoxide
(DMSO). Recombinant human HGF (rHGF) was pur-
chased from R&D Systems (Minneapolis, MN, USA) and
reconstituted in PBS with 0.1 % bovine serum albumin.
Quantitative real-time polymerase chain reaction
TRIzol RNA Isolation Reagents (Life Technologies, Tokyo,
Japan) were used for total RNA extraction according to
Ozawa et al. BMC Cancer  (2015) 15:451 Page 4 of 12the manufacturer’s instruction. Reverse transcription was
then performed in a thermal cycler using appropriate
amounts of total RNA. The measurement of mRNA ex-
pression was performed using a Light Cycler equipment
(Roche, Basel, Switzerland). The sequence of the primers
used was as follows: c-Met forward: 5′-CACTTCTGAG
AAATTCATCAGGCTGTGAAG-3′, reverse: 5′-AGAGG
ACTTCGCTGAATTGACCCATG-3′, and HGF forward:
5′-TGTGCCATTCCAAATCGTCCTGGT-3′, reverse: 5′-
TCAACAAACATGACTCTCCAGTAGTTGTCT-3′. RPL
13A was used as a housekeeping gene for mRNA
quantification.
Immunoblotting analysis
For protein extraction, three ESCC cell lines (KYSE150,
170, and 180) were lysed and scraped in Mammalian
Protein Extraction Regent with 2 % protease inhibitor,
2 % phosphatase inhibitor, and 1 % ethylenediamine-
tetraacetic acid. Each protein sample was subsequently
resolved in 10 % sodium dodecyl polyacrylamide gels
and transferred onto nitrocellulose membranes using
Amersham ECL semi-dry blotters (GE Healthcare,
Tokyo, Japan). After blocking of nonspecific binding
for 1.5 h in 5 % skimmed milk, the membranes were
reacted with primary antibodies at 4 °C overnight. They
were then washed with Tris-buffered saline and reacted
with secondary antibody for 1 h. Protein expression was
visualized using ChemiDoc™ XRS+ System (BIORAD,
Tokyo, Japan). For quantification of protein expression
by c-Met and components of its downstream signaling
pathways, KYSE170 cells were cultured in fetal bovine
serum (FBS)-free medium for 48 h prior to protein ex-
traction. The quantitative determination was performed
using the quantification tool of Image LabTM software
(BIORAD). The primary antibodies used are summa-
rized in Table 2.
Invasion assay
The invasive properties of ESCC cells were determined
using Cell Culture Inserts with transparent PET mem-
brane (24-well, 8.0-μm pore size) and their companion
plates (BD Falcon, San Jose, CA, USA). After culturingTable 2 Primary antibodies used for immunoblotting analysis
Antibody Source Clon
c-Met β Rabbit P
Phospho-Met (pY1234/35) Rabbit P
Akt (Pan) Rabbit M (1
Phospho-Akt (Ser473) Rabbit P
p44/42 MAPK (Erk1/2) Rabbit M (1
Phospho-P44/42 MAPK (Erk1/2) (Thr202/Tyr204) Rabbit M (2
P Polyclonal, M Monoclonal, CST Cell Signaling Technology, MAPK mitogen-activatedfor 24 h in an FBS-free medium, three ESCC cell lines
(KYSE150, 170, and 180) were seeded in the upper
chambers (3 × 105 cells/chamber for KYSE170 and 1 × 105
cells/chamber for KYSE 150 and 180) with PF-2341066
treatment or vehicle control. These upper chambers
were inserted in to a 24-well lower chamber containing
FBS-free medium supplemented with 50 ng/ml of HGF
or vehicle control. After the plate was cultured for 24 h
at 37 °C with 5 % CO2, each upper chamber filter
was fixed with methanol and counterstained with
hematoxylin. The number of invasive tumor cells for
each filter membrane was then counted in high-power
fields.
Cell proliferation assay
ESCC cells were counted using the Cell Counting Kit-8
(Dojindo, Kumamoto, Japan). Three ESCC cell lines
(KYSE150, 170, and 180) were seeded in a 96-well plate
(1 × 104 cells/well). After the plate was cultured for 24 h
in FBS-free medium, the medium was switched to one
with or without 50 ng/ml of HGF and PF-2341066.
Then, WST-8, a highly water-soluble tetrazolium salt,
was added to each well at 24 h after PF-2341066 treat-
ment, and absorbance at 450 nm was measured using a
microplate reader (BIORAD). Equivalent volumes of
DMSO were used as vehicle controls.
Statistical analysis
Pearson’s chi-square test was used to assess the correl-
ation of immunohistochemical protein expression with
various clinicopathological features. P-values of <0.05
were considered statistically significant. Survival curves
were generated using the Kaplan-Meier method, and
differences were compared using the log-rank test. Uni-
variate and multivariate analyses were performed using
Cox’s proportional hazards model. The multivariate ana-
lysis performed in this study included clinicopathological
features with a P-value of <0.05 in the antecedent uni-
variate analysis, c-Met expression, and HGF expression.
Student’s t-test was used for the analysis of preoperative
biochemical values of blood samples, preoperative respira-
tory function test, proliferation assay, invasion assay, andality (clone number) Dilution Provider (catalog number)
×200 IBL, Japan (18321)
×500 CST, USA (#3126)
1E7) ×1000 CST (#4685)
×500 CST (#4060)
37 F5) ×1000 CST (#4695)
0G11) ×500 CST (#4376)
protein kinase
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were performed using JMP Pro 9 software (SAS Institute,
Cary, CA, USA).
Results
c-Met and HGF expression in ESCC tissue specimens
Figure 1 shows representative microscopic images of
c-Met and HGF immunostaining. c-Met high expression
was detected in 69.2 % (72/104) of the patients exam-
ined. c-Met immunoreactivity was mostly detected in
the cytoplasm of cancer cells (Fig. 1b). HGF immuno-
reactivity was mainly present in the cytoplasm of car-
cinoma cells (Fig. 1d) and intratumoral stromal cells,
including cancer-associated fibroblasts (CAF). HGF im-
munoreactivity of intratumoral stromal cells was hetero-
geneous and difficult to evaluate. Therefore, we only
considered cytoplasmic immunoreactivity in carcinoma
cells for statistical analysis.
The association between c-Met/HGF status and patients’
clinicopathological features
c-Met status was significantly correlated with tumor
depth (P = 0.013) and pathological stage (P = 0.010). On
the other hand, HGF status was significantly correlated
with tumor differentiation (P = 0.024), tumor depth (P =
0.028), lymph node metastasis (P = 0.014), and patho-
logical stage (P = 0.022). However, no statistically signifi-
cant correlation was detected between c-Met and HGF
status of the patients. Results of the correlation analysisFig. 1 Representative microscopic images of low and high c-Met and HGF imm
shown was completely negative for c-Met immunoreactivity. b c-Met high expr
the cytoplasm of carcinoma cells. c HGF low expression; the representative case
expression; the representative case demonstrated HGF immunoreactivity in theof ESCC patients’ clinicopathological variables and c-
Met/HGF immunoreactivity in carcinoma cells are sum-
marized in Table 1.
The association between c-Met/HGF high expression and
patient survival
The 5-year overall survival rate of patients with c-Met
high expression was significantly lower than that of those
in the c-Met low expression group (P = 0.022) (Fig. 2a).
This difference was even more pronounced in cause-
specific survival (CSS) (P = 0.015) (Fig. 2b). Univariate ana-
lysis revealed that patient survival was significantly associ-
ated with sex (P = 0.036), lymphatic invasion (P = 0.015),
tumor depth (P = 0.015), lymph node metastasis (P <
0.001), pathological stage (P < 0.001), and c-Met expres-
sion (P = 0.017) (Table 3). In addition, multivariate analysis
identified high expression of c-Met (P = 0.033) and lymph
node metastasis (P = 0.025) as independent prognostic
factors (Table 4). However, no significant differences
in 5-year overall survival and CSS between patients
with high and low HGF expression were observed.
Patients with high HGF expression tended to have a
lower survival rate (Additional file 1), but the difference
did not reach statistical significance. Furthermore,
patients with high c-Met and HGF demonstrated worse
clinical outcomes than others, but the 5-year overall
survival of those with such a combined status of c-Met
and HGF was not significantly different from that of
others (Additional file 2).unohistochemical staining. a c-Met low expression; the representative case
ession; the representative case demonstrated c-Met immunoreactivity in
shown was completely negative for HGF immunoreactivity. d HGF high
cytoplasm of carcinoma cells. HGF, hepatocyte growth factor
Fig. 2 Kaplan-Meier curves according to c-Met expression. a The 5-year overall survival of ESCC patients with high c-Met expression was signifi-
cantly worse than that of patients with low c-Met expression. b The differences in cause-specific survival between the two groups of ESCC pa-
tients were even more statistically significant than those observed in their 5-year overall survival. ESCC, esophageal squamous cell carcinoma
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preoperative serum biochemical test and respiratory
function test
There were no significant correlations between c-Met/
HGF expression and preoperative AST, ALT, ICG-R15,
%VC and FEV 1.0 % in ESCC patients (data not shown).Table 3 Univariate analysis of patients’ 5-year overall
survival
Variable P-value Hazard




Sex (male/female) 0.036a 2.621 (1.057–8.724)






(well/poor) 0.143 0.484 (0.185–1.290)
(moderate/poor) 0.41 0.710 (0.340–1.671)
Growth pattern (INFa/INFb) 0.725 0.878 (0.402–1.774)
(INFa/INFc) 0.158 0.528 (0.216–1.290)
(INFb/INFc) 0.193 0.602 (0.297–1.316)
Lymphatic invasion (ly1–3/ly0) 0.015* 2.392 (1.174–5.536)
Venous invasion (v1–3/v0) 0.763 1.109 (0.581–2.295)




Distant metastasis (pM1/pM0) 0.086 2.308 (0.875–5.069)
Pathological stage (pStage III–IV/I–II) <0.001a 3.403 (1.840–6.620)
c-Met expression (high/low) 0.017a 2.291 (1.153–5.073)
HGF expression (high/low) 0.194 1.477 (0.817–2.662)
CI confidence interval, HGF hepatocyte growth factor, INF infiltration
a indicates statistical significancec-Met and HGF expression in ESCC cell lines
c-Met and HGF mRNA was detectable in all three cell
lines examined (Fig. 3a). The amounts of HGF mRNA
were much lower than those of c-Met (Fig. 3b). We also
confirmed the expression of c-Met and HGF proteins in
all three cell lines using immunoblotting (Fig. 3c). Of
these, KYSE170 had the highest amounts of c-Met mRNA.
The invasion capacity of ESCC cells was promoted by
rHGF stimulation but inhibited by PF-2341066
The invasiveness of KYSE170 cells was promoted by
rHGF. When both rHGF and PF-2341066 were absent,
the number of invaded cells in invasion assay was 31.6 ±
9.0, but that increased to 99.0 ± 25.6 when only rHGF
was added (P = 0.0019). However, the number of invaded
cells decreased under PF-2341066 treatment to 54 ± 13.3
at 10 nM, 27.6 ± 4.5 at 100 nM, 36.2 ± 12.3 at 500 nM,
and 25.2 ± 5.4 at 1 μM. In addition, treatment with 100
nM, 500 nM, and 1 μM of PF-2341066 significantly
decreased cell invasiveness (P = 0.001, 0.003, and <0.001)
(Fig. 4). KYSE 180 cells demonstrated similar invasive
tendencies as those observed in KYSE 170 cells, but the
changes were not statistically significant. However, the
invasion capacity of KYSE 150 cells did not differ signifi-
cantly under rHGF pre-stimulation and/or PF-2341066
treatment.
Inhibition of ESCC cell proliferation by PF-2341066
The proliferation of the three ESCC cell lines (KYSE150,
170 and 180) under PF-2341066 treatment was evaluated
as a decrease percentage compared to control (rHGF+/
PF-2341066-). When 1 μM of PF-2341066 was added, the
proliferation of KYSE150 cells decreased 16 % (P = 0.001);
that of KYSE170 decreased 11 % (P = 0.11), and KYSE180
cell proliferation decreased 16 % (P = 0.003) (Fig. 5).
Table 4 Multivariate analysis of patients’ 5-year overall
survival
Variable P-value Relative risk (95 % CI)
Sex (male/female) 0.193 1.944 (0.737–6.710)
Lymphatic invasion (ly1–3/ly0) 0.222 1.628 (0.756–3.925)
Tumor depth (pT3–4/pT1–2) 0.26 1.911 (0.644–7.047)
Lymph node metastasis (pN1/pN0) 0.025a 3.852 (1.169–16.335)
Pathological stage (pStage III–IV/I–II) 0.814 0.856 (0.215–2.898)
c-Met expression (high/low) 0.033a 2.237 (1.066–5.190)
HGF expression (high/low) 0.821 1.075 (0.572–2.012)
CI confidence interval, HGF hepatocyte growth factor
aindicates statistical significance
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untreated cells and those receiving rHGF but not PF-
2341066 (control), incremental cell proliferation was
observed in all three cell lines, but the differences did
not reach statistical significance except for KYSE150.
Activation of c-Met and its downstream signaling pathways
affected by PF-2341066
The activation of c-Met and its downstream signaling
pathway was evaluated via immunoblotting analysis of
KYSE170 cells, which demonstrated marked inhibitory
effects in the invasion assay. In the absence of rHGF,
total c-Met protein and only weak phospho-c-Met ex-
pression were detected. In contrast, the expression of
phospho-MAPK and phospho-Akt was detected without
rHGF. However, when rHGF was added, phosphor-c-Fig. 3 mRNA and protein levels of c-Met and HGF in ESCC cell lines. a Elec
each bands as expected for c-Met and HGF. b Quantitative analysis reveale
mRNA in all tested lines. c Western blot analysis confirmed the expression of c
factor; ESCC, esophageal squamous cell carcinomaMet was clearly detected, and the immunoreactivity of
both phospho-MAPK and phospho-Akt was more prom-
inent than that in the absence of rHGF (Fig. 6). Expression
of the three phosphorylated proteins was remarkably
inhibited by PF-2341066 (Fig. 6). Quantitative analysis of
immunoblotting results demonstrated that phospho-c-
Met expression significantly decreased in a concentration-
dependent manner under PF-2341066 treatment (23.7 %
decrease at 10 nM; 58.6 % at 100 nM, P < 0.0001; 64.6 %
at 500 nM, P < 0.0001; and 65.3 % at 1 μM, P < 0.0001)
(Fig. 7). In addition, phospho-Akt expression significantly
decreased to 14.0 % at 10 nM, 68.5 % at 100 nM, 67.1 % at
500 nM, and 59.3 % at 1 μM, whereas that of phospho-
MAPK significantly decreased to 66.5 % at 100 nM, 65.0 %
at 500 nM, and 54.1 % at 1 μM (Fig. 7).
Discussion
The overexpression of c-Met has been reported in ESCC
[32], but its biological and clinical significance remains
virtually unknown [33], despite the reported roles of
paracrine signaling from CAF, involving HGF, in ESCC
invasion by Grugan et al. [32]. In addition, elevated
serum or tissue HGF levels have been reported to be as-
sociated with adverse clinical outcome in ESCC patients
[34, 35]. The results of our present study indicated that
elevated expression of c-Met was significantly correlated
with tumor depth and pathological stage of ESCC
patients. In addition, increased HGF expression was sig-
nificantly correlated with tumor differentiation, tumor
depth, lymph node metastasis, and pathological stage.trophoretic analysis of the polymerase chain reaction products showed
d the highest c-Met level in KYSE170 and very small amounts of HGF
-Met and HGF proteins in all three cell lines. HGF, hepatocyte growth
Fig. 4 Variation in invasive capacity of three ESCC cell lines. In KYSE170 cells, the invasion capacity of cells was markedly increased by rHGF
pre-stimulation and decreased by PF-2341066. KYSE 180 cells demonstrated similar invasive tendencies as those observed in KYSE 170 cells, but
the changes were not statistically significant. However, the invasion capacity of KYSE 150 cells did not differ significantly under rHGF pre-stimulation
and/or PF-2341066 treatment. Green statistical comparison bars and stars represent the KYSE170 cell line. rHGF, recombinant hepatocyte growth factor
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because the cut-offs were determined via patients’ sur-
vival. Our survival analysis revealed that patients with
high c-Met expression had significantly worse 5-year
overall survival and CSS than those without. Further-
more, the statistical difference of CSS between the two
groups was more prominent than that of 5-year overall
survival. This result suggested that c-Met high expres-
sion could be a prognostic factor in ESCC patients. In
fact, c-Met status of carcinoma cells was identified as
an independent prognostic factor for clinical outcomes
in these patients. Although c-Met overexpression is
thought to promote tumor progression and/or serve as
an independently poor prognostic factor in variousFig. 5 Variation in cell proliferation of three ESCC cell lines. In all three cell
pre-stimulation and decreased by PF-2341066 were only limited to about l
represent the KYSE150 and KYSE180 cell lines, respectivelycarcinomas [5–18], to the best of our knowledge, this
study was the first investigation to report its clinical sig-
nificance in ESCC. Our results demonstrated that c-Met
overexpression could promote cell growth and invasion
in ESCC.
However, the correlation between c-Met and HGF ex-
pression did not reach statistical significance. This may
be explained by the fact that HGF is secreted by carcin-
oma cells as well as CAFs [32] and in other inflamma-
tory processes, including alcoholic hepatitis, cirrhosis,
smoking, and chronic obstructive pulmonary disease
[36, 37]. We therefore analyzed the correlation between
c-Met/HGF immunoreactivity and preoperative levels of
%VC, FEV 1.0 %, CRP, ICG-R15, AST, and ALT owinglines examined, the variations of cell proliferation increased by rHGF
ess than 15 %. Blue and red statistical comparison bars and stars
Fig. 6 Western blot analysis of KYSE170 cells. Immunoblot analysis revealed that phospho-c-Met protein expression was markedly increased by
rHGF pre-stimulation and decreased by PF-2341066 treatment. Similarly, phospho-Akt and phosphor-MAPK protein expression was also increased
by rHGF pre-stimulation and decreased by PF-2341066. rHGF, recombinant hepatocyte growth factor; MAPK, mitogen-activated protein kinase
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smoking history in ESCC patients, but found no signifi-
cant correlation. Nonetheless, HGF immunoreactivity
in CAFs was heterogeneous and difficult to evaluate.
Therefore, functional HGF to activate c-Met was reason-
ably postulated to be secreted from not only CAFs and
other inflammatory processes but also tumor cells, al-
though further investigations for clarification is needed.
In this study, we also confirmed mRNA and protein
expression of c-Met and HGF in three ESCC cell lines.
Saeki et al. [33] previously reported c-Met mRNA and
protein expression in six different ESCC cell lines. Hu
et al. [29] also described the overexpression of c-Met
mRNA and protein in ESCC compared to normal epi-
thelium. In our study, KYSE170 cells showed the highest
expression of c-Met mRNA. On the other hand, mRNA
and protein levels of HGF in ESCC cell lines are un-
known because the HGF secretory mechanism has been
postulated to be derived via paracrine signaling from
CAFs [32, 34]. However, in this study, we did detect
HGF expression in all three ESCC cell lines studied
albeit low levels.
The results of our in vitro studies demonstrated the
important role of HGF as a c-Met activator and the effi-
cacy of the c-Met small-molecule inhibitor PF-2341066,
especially in KYSE170 cells with the highest c-MetmRNA expression among the three ESCC cell lines
tested. The invasive potential of KYSE170 cells was
significantly increased by rHGF pre-stimulation and
decreased by PE-2341066 treatment. In addition, the
changes in phospho-c-Met protein levels were also
highly HGF dependent. However, the inhibitory effects
of ESCC cell proliferation by PF-2341066 were only mar-
ginally detected in the three cell lines examined in our
study. These results indicated that the inhibitory effects
of PF-2341066 in ESCC were detected only in c-Met
high expression cells, and the drug mainly suppressed
cell invasive potential rather than cell proliferation. c-
Met activation is well known to occur via homodimeri-
zation and autophosphorylation upon binding to its
specific ligand, HGF, under physiological conditions [3].
However, in cancer, c-Met was not only activated by the
above-mentioned HGF-dependent paracrine and auto-
crine mechanisms but also via other HGF-dependent or
independent fashions such as in cases of c-Met gene
amplification or mutations [28]. The results of our study
demonstrated that c-Met was activated by HGF stimula-
tion in ESCC, as in other malignancies. Although Kato
et al. reported approximately 1 % (2/196) prevalence
of c-Met gene amplification in ESCC patients [27], the
status of c-Met gene mutation or amplification in ESCC
is virtually unknown.
Fig. 7 Quantitative analysis of KYSE170 cells’ immunoblot. The phosphorylated forms of c-Met, Akt, and MAPK were significantly increased by
rHGF pre-stimulation and decreased under PF-2341066 treatment. However, the protein levels of total c-Met, Akt, and MAPK were not affected by
such treatments
Ozawa et al. BMC Cancer  (2015) 15:451 Page 10 of 12The important downstream signaling of c-Met in-
cludes the MAPK cascade and PI3K/Akt signaling
pathway, which mainly regulates cell proliferation and
motility [3]. We showed that ESCC cell invasive property
was significantly inhibited by PF-2341066 in the
presence of rHGF in one of the three ESCC cell lines
examined. In addition, we also demonstrated that the
expression levels of phosphorylated c-Met, MAPK, and
Akt proteins were all significantly down regulated by
treatment with PF-2341066. Marked inhibition of MAPK
and Akt signaling were considered important. Zillhardt
et al. reported the inhibition of MAPK and Akt signalingby PF-2341066 in ovarian cancer cells [38], which was
consistent with our results. Knowles et al. reported
the inhibition of Akt signaling but not of the MAPK
cascade by PF-2341066 in head and neck squamous cell
carcinoma cells, possibly due to the high basal level of
phosphorylated MAPK in these cells prior to HGF
stimulation [39]. Our results indicated that the motility
of ESCC cells, at least in those with high c-Met expres-
sion, was regulated by c-Met activation upon HGF
stimulation, and the process was mediated by both
MAPK and Akt signaling pathways. Therefore, c-Met
could be a potential molecular therapeutic target for the
Ozawa et al. BMC Cancer  (2015) 15:451 Page 11 of 12treatment of ESCC with high c-Met expression as in
other human malignancies [18, 38–41]. However, c-Met
regulates many downstream signaling mediators, including
not only MAPK and Akt but also a signal transducer and
activator. Therefore, further investigations are needed to
elucidate c-Met functional behavior in ESCC.
PF-2341066 is also known to inhibit the protein
activation processes resulted from gene rearrangement
of anaplastic lymphoma kinase and ROS1 tyrosine
kinase [42, 43] in addition to c-Met inhibition. However,
to the best of our knowledge, such rearrangements have
not been reported in ESCC. Additionally, our results
demonstrated that the inhibition of cell function by
PF-2341066 depended on the presence of HGF, a c-Met
specific ligand. Thus, PF-2341066 functioned as an efficient
c-Met inhibitor in the context of our study.
Conclusion
In conclusion, the results of our study identified c-Met
expression in carcinoma cells as an independent prog-
nostic factor for ESCC and demonstrated the potential
of c-Met as a molecular therapeutic target for the treat-
ment of high c-Met expressing ESCC. However, further
genetic and/or biological investigations are warranted.
Additional files
Additional file 1: Patient survival according to HGF expression.
No statistically significant differences in 5-year overall survival (A)
or cause-specific survival (B) according to HGF expression were
observed via the log-rank test. However, patients with high HGF
expression tended to have a lower survival rate. HGF, hepatocyte growth
factor.
Additional file 2: Patient survival according to the combination
expression of c-Met and HGF. Patients with high c-Met and HGF
demonstrated adverse clinical outcomes compared to others, but the
5-year overall survival of those with a combination of high c-Met and
HGF was not significantly different to that of other patient groups.
HGF, hepatocyte growth factor.
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